BR112017006705A2 - inibidores de biossíntese de sulfato de heparan para o tratamento de doenças - Google Patents

inibidores de biossíntese de sulfato de heparan para o tratamento de doenças

Info

Publication number
BR112017006705A2
BR112017006705A2 BR112017006705A BR112017006705A BR112017006705A2 BR 112017006705 A2 BR112017006705 A2 BR 112017006705A2 BR 112017006705 A BR112017006705 A BR 112017006705A BR 112017006705 A BR112017006705 A BR 112017006705A BR 112017006705 A2 BR112017006705 A2 BR 112017006705A2
Authority
BR
Brazil
Prior art keywords
treating diseases
heparan sulfate
biosynthesis inhibitors
compounds
sulfate biosynthesis
Prior art date
Application number
BR112017006705A
Other languages
English (en)
Inventor
Wang Bing
R Luedtke Gregory
Spyvee Mark
Bhagwat Shripad
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of BR112017006705A2 publication Critical patent/BR112017006705A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a compostos de fórmula i, métodos de preparação de tais compostos, composições farmacêuticas e medicamentos que contêm esses compostos e métodos de utilização de tais compostos para tratar ou prevenir as doenças ou condições com necessidade de inibição da biossíntese de sulfato de heparan.
BR112017006705A 2014-10-09 2015-10-08 inibidores de biossíntese de sulfato de heparan para o tratamento de doenças BR112017006705A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062036P 2014-10-09 2014-10-09
PCT/US2015/054761 WO2016057834A1 (en) 2014-10-09 2015-10-08 Heparan sulfate biosynthesis inhibitors for the treatment of diseases

Publications (1)

Publication Number Publication Date
BR112017006705A2 true BR112017006705A2 (pt) 2017-12-26

Family

ID=55653801

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017006705A BR112017006705A2 (pt) 2014-10-09 2015-10-08 inibidores de biossíntese de sulfato de heparan para o tratamento de doenças

Country Status (16)

Country Link
US (1) US20190151312A1 (pt)
EP (1) EP3204009A4 (pt)
JP (1) JP2017530991A (pt)
KR (1) KR20170072242A (pt)
CN (1) CN107106561A (pt)
AR (1) AR102213A1 (pt)
AU (1) AU2015330846A1 (pt)
BR (1) BR112017006705A2 (pt)
CA (1) CA2963607A1 (pt)
IL (1) IL251497A0 (pt)
MA (1) MA40957A (pt)
MX (1) MX2017004618A (pt)
RU (1) RU2017115305A (pt)
TW (1) TW201629051A (pt)
WO (1) WO2016057834A1 (pt)
ZA (1) ZA201703003B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107922350B (zh) * 2015-09-11 2022-04-19 大日本住友制药株式会社 新的苯并咪唑化合物及其医药用途
AU2018241406B2 (en) 2017-03-28 2021-11-11 Basf Se Pesticidal compounds
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
CN109020957B (zh) * 2017-06-12 2023-01-13 南京天印健华医药科技有限公司 作为mnk抑制剂的杂环化合物
CN110582489B (zh) 2017-06-30 2023-10-27 北京泰德制药股份有限公司 Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
EP3421465B1 (en) 2017-06-30 2022-10-26 Beijing Tide Pharmaceutical Co., Ltd. Rho-associated protein kinase inhibitor, pharmaceutical composition comprising the same, as well as preparation method and use thereof
KR102469161B1 (ko) 2017-06-30 2022-11-23 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
CN107445899A (zh) * 2017-07-19 2017-12-08 枣庄学院 一种苯并咪唑类化合物及其制备方法
CN108997343A (zh) * 2018-04-17 2018-12-14 丁敏 一种治疗小儿热性惊厥的药物组合物的制备方法
CN108794470B (zh) * 2018-07-25 2020-06-26 上海毕得医药科技有限公司 一种6-肼基-1H-吡唑并[3,4-b]吡啶及其下游产品的合成方法
US11053501B2 (en) 2018-11-30 2021-07-06 The Penn State Research Foundation Methods of treating neurodegenerative disease by inhibiting N-deacetylase N-sulfotransferase
KR102344561B1 (ko) * 2019-11-15 2021-12-29 일동제약(주) Glp-1 수용체 작용제 및 이의 용도
WO2021127282A1 (en) * 2019-12-18 2021-06-24 Stinginn Llc Substituted 1,2, 4-triazoles and methods of use
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2507100C (en) * 2002-11-21 2012-10-09 Chiron Corporation 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
WO2009066084A1 (en) * 2007-11-21 2009-05-28 F. Hoffmann-La Roche Ag 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors
WO2012003264A1 (en) * 2010-06-30 2012-01-05 Amgen Inc. Nitrogen containing heterocyclic compounds as pik3 -delta inhibitors

Also Published As

Publication number Publication date
MA40957A (fr) 2017-09-19
MX2017004618A (es) 2017-10-23
RU2017115305A (ru) 2018-11-14
CN107106561A (zh) 2017-08-29
ZA201703003B (en) 2018-04-25
JP2017530991A (ja) 2017-10-19
KR20170072242A (ko) 2017-06-26
WO2016057834A1 (en) 2016-04-14
CA2963607A1 (en) 2016-04-14
AU2015330846A1 (en) 2017-05-18
AR102213A1 (es) 2017-02-15
TW201629051A (zh) 2016-08-16
EP3204009A1 (en) 2017-08-16
US20190151312A1 (en) 2019-05-23
WO2016057834A9 (en) 2017-04-13
IL251497A0 (en) 2017-05-29
EP3204009A4 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
BR112017020999A2 (pt) inibidores de indolamina-2,3-dioxigenase para o tratamento de câncer
PH12018500981A1 (en) Treatment of osteoarthritis
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam
MY195427A (en) Jak Kinase Inhibitor Compounds for Treatment of Respiratory Disease
NI201700056A (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzhéimer
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
BR112016015706A8 (pt) composto, uso do mesmo e composição farmacêutica
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
BR112015032595A2 (pt) inibidores de ido
BR112015022462A2 (pt) inibidores de ido
MX2016016115A (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
UY33246A (es) Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
BR112017010311A2 (pt) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
BR112017000132A2 (pt) composto, composição farmacêutica e método de tratamento ou prevenção de uma doença responsiva à inibição da atividade de pi3k
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]